PRO-122

Phase 3Small molecule

LLaboratorios Sophia S.A de C.V.

PRO-122 is one of 41 small molecule programs targeting Ocular Hypertension. It is currently in Phase 3.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Ocular HypertensionActive, not recruiting

Open-Angle GlaucomaActive, not recruiting

Ocular HypertensionPhase 3

Active, not recruiting

Open-Angle GlaucomaPhase 3

Active, not recruiting

Competition

Competitive Landscape

187 competitors in Ocular Hypertension

#DrugCompanyPhaseTrials

Timolol Maleate

CCidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)

Phase 3

9 2

Comparator: Pbo

Merck & Co.

Phase 3

2 3

Azopt

Novartis

Phase 3

1 4

Ocupress

AbbVie

Phase 3

1 5

LUMIGAN

AbbVie

Phase 3

2 6

Krytantek

AbbVie

Phase 3

2 7

Preservative-Free Tafluprost

Merck & Co.

Phase 3

2 8

PRO-122

LLaboratorios Sophia S.A de C.V.

Phase 3

1 9

Reference - LUMIGAN

AAmneal Pharmaceuticals, LLC

Phase 3

1 10

Duotrav

AAlcon Research

Phase 3

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Open-Angle Glaucoma1 trial

PRO-122 Versus Concomitant Therapy in Subjects With Uncontrolled Primary Open-angle Glaucoma (PRO-122LATAM)

Terminated·LLaboratorios Sophia S.A de C.V.·Phase 3·NCT03193333·51 enrolled

Ocular Hypertension1 trial

Non-inferiority of PRO-122 Ophthalmic Solution vs KRYTANTEK Ofteno® in Glaucoma or Ocular Hypertension (CONFORTK)

Completed·LLaboratorios Sophia S.A de C.V.·Phase 3·NCT03257813·60 enrolled

MPA1 trial

Safety and Tolerability of the Preservative-free Ophthalmic Solution PRO-122 Compared With Krytantek Ofteno®

Completed·LLaboratorios Sophia S.A de C.V.·Phase 1·NCT03966365·24 enrolled

Sources

References

[1]
ClinicalTrials.gov — 3 trial records for PRO-122. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — PRO-122 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for PRO-122. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Laboratorios Sophia S.A de C.V. company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 3[1]
Company: LLaboratorios Sophia S.A de C.V.

PRO-122

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Open-Angle Glaucoma1 trial

Ocular Hypertension1 trial

MPA1 trial

References

Drug Info

Quick Facts

Related News